Skip Navigation


IJE Advance Access originally published online on October 30, 2006
International Journal of Epidemiology 2006 35(6):1579-1585; doi:10.1093/ije/dyl207
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
35/6/1579    most recent
dyl207v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (8)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Morgan, O.
Right arrow Articles by Hickman, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Morgan, O.
Right arrow Articles by Hickman, M.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published by Oxford University Press on behalf of the International Epidemiological Association © The Author 2006; all rights reserved.

Association between availability of heroin and methadone and fatal poisoning in England and Wales 1993–2004

Oliver Morgan1,2,*, Clare Griffiths2 and Matthew Hickman3

1 Department of Primary Care and Social Medicine, Imperial College London, London, UK.
2 Health and Care Division, Office for National Statistics, London, UK.
3 Department of Social Medicine, University of Bristol, Bristol, UK.

* Corresponding author. Health and Care Division, Office for National Statistics, 1 Drummond Gate, London SW1V 2QQ, UK. E-mail: Omorgan{at}bigfoot.com


   Abstract

Background The UK heroin market is the biggest in Europe and ~70% of heroin deaths are due to fatal poisoning. Methadone treatment for heroin addiction in the UK, the ‘British system’, is unique as it is largely provided by General Practitioners.

Methods The Office for National Statistics provided data on deaths, the Home Office provided law enforcement data on drug seizures and the Department of Health data on prescriptions. For methadone treatment we calculated the death rate per 1000 patient years. We used Spearman's rank correlation to assess the association between illicit drug seizures for heroin and methadone and deaths.

Results Between 1993 and 2004 there were 7072 deaths involving heroin/morphine (86% males) and 3298 deaths involving methadone (83% male). From 1993–1997, directly age-standardized mortality rates for males were similar for both drugs, increasing from ~5 to 15 per million. Mortality rates for heroin continued to increase until 2000, subsequently decreasing from 30 to 20 per million by 2003, and rising again to 24 per million in 2004. In contrast, mortality rates for methadone decreased between 1997 and 2004 to just above 1993 levels. Among females the mortality rate for both drugs was lower than for males throughout the study period, remaining relatively stable. Methadone deaths per 1000 patient years remained similar between 1993 and 1997, after which they fell by three quarters. For both heroin/morphine and methadone, deaths were strongly associated with seizures (Spearmans' coefficient for males: heroin, P = 0.95, P < 0.001 and methadone, P = 0.83, P = 0.0013).

Conclusions Our study suggests the ‘British System’ can deliver substantial expansion of treatment without increased mortality risk. The fall in heroin/morphine deaths since 2000 may also be an indication of success of increasing methadone treatment. Data on mortality risk is needed to determine whether increased methadone treatment has reduced drug-related deaths.


Keywords substance abuse, Intravenous/epidemiology, substance abuse, Intravenous/mortality, methadone, heroin

Accepted 23 August 2006


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
J Public Health (Oxf)Home page
M. Hickman, V. Hope, B. Coleman, J. Parry, M. Telfer, J. Twigger, C. Irish, J. Macleod, and H. Annett
Assessing IDU prevalence and health consequences (HCV, overdose and drug-related mortality) in a primary care trust: implications for public health action
J Public Health, September 1, 2009; 31(3): 374 - 382.
[Abstract] [Full Text] [PDF]


Home page
Am J EpidemiolHome page
M. J. Sweeting, V. D. Hope, M. Hickman, J. V. Parry, F. Ncube, M. E. Ramsay, and D. De Angelis
Hepatitis C Infection Among Injecting Drug Users in England and Wales (1992-2006): There and Back Again?
Am. J. Epidemiol., August 1, 2009; 170(3): 352 - 360.
[Abstract] [Full Text] [PDF]


Home page
BMJHome page
C McCowan, B Kidd, and T Fahey
Factors associated with mortality in Scottish patients receiving methadone in primary care: retrospective cohort study
BMJ, June 16, 2009; 338(jun16_4): b2225 - b2225.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.